Armistice Capital’s Biohaven BHVN Stock Holding History

Armistice Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-250,000	Closed	-$3.75M	–	380
2025 Q3	$3.75M	Buy	+250,000	New	+$3.64M	0.06%	126

Other funds holding BHVN

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $173M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital's BHVN Position: Q3 2025 in Review

Armistice Capital sold out of Biohaven (BHVN) in Q3 2025, closing a stake of 2,136,000 shares — an estimated $31.1M sold.

Armistice Capital first reported a position in BHVN in Q3 2022 and held it in 12 quarters. The position peaked at $64.2M in Q4 2023. 264 funds tracked by Wall St. Rank hold BHVN as of Q3 2025.

Armistice Capital reported no remaining Biohaven position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 2,136,000 Biohaven shares in Q3 2025, an estimated $31.1M.
Armistice Capital first reported a position in Biohaven in Q3 2022 and held it in 12 quarters.
Armistice Capital's Biohaven position peaked at $64.2M in Q4 2023.
264 funds tracked by Wall St. Rank held Biohaven as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.